Here are the 10-Q quarterly reports from Kyntra Bio, Inc. (KYNB) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow KYNB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KYNB filings page.
Kyntra Bio, Inc. reported results for the quarter ended June 30, 2026, highlighted by a non‑cash $30.9 million gain from the deconsolidation of its bankrupt European subsidiary, FibroGen Europe. This produced income from continuing operations of $12.0 million (basic and diluted EPS $2.96), compared with a $13.7 million loss a year earlier, despite an operating loss of $17.6 million.
Total revenue from continuing operations was $(1.5) million for the quarter and $2.3 million for the first half, driven mainly by drug product sales and variable‑consideration true‑ups under Astellas agreements. Operating costs rose to $16.1 million in the quarter and $33.7 million year‑to‑date, reflecting higher legal expenses, Phase 2 FG‑3246 trial spending and product costs, partially offset by lower headcount, facilities and stock‑based compensation.
For the first six months, loss from continuing operations narrowed to $3.2 million from $30.4 million a year earlier, but operating activities used $17.9 million of cash versus $15.4 million provided in the prior period. Cash, cash equivalents, short‑ and long‑term investments and accounts receivable totaled about $95.7 million at June 30, 2026. Management states this liquidity is expected to fund planned operations for at least 12 months. The company remains focused on its FG‑3246 ADC program in mCRPC and preparing a Phase 3 program for oral roxadustat in lower‑risk MDS.
Kyntra Bio, Inc. reported first-quarter 2026 revenue of $3.7 million, up from $2.7 million a year earlier, driven mainly by $3.5 million of drug product sales of roxadustat API and bulk product to Astellas. Operating costs and expenses were $17.6 million, roughly flat year over year.
The company posted a loss from continuing operations of $15.1 million, or $3.74 per share, compared with a loss of $16.8 million, or $4.15 per share, in 2025. Net loss was $15.2 million versus net income of $4.6 million last year, when results included $21.4 million of income from discontinued China operations. Cash, cash equivalents, short- and long-term investments, and accounts receivable totaled about $100.3 million, and management believes this will fund operations for at least 12 months. Kyntra continues to develop FG-3246 for metastatic castration-resistant prostate cancer and advance roxadustat into a planned Phase 3 trial for anemia in lower-risk MDS.